Mrices,

             I've sorted through the data and spoken to someone that was at the Annual Stockholders Meeting. Due to the impending scientific publication, I believe the company is being somewhat vague with the specific data. I think the data released last Thursday was additional data and sub endpoints to be used for AVXL's FDA submission. Nowhere does AVXL retract any of the previously released data endpoints. We have three possibilities coming before the end of the year:

 

1) Scientific Alzheimer's Publication with Fully released data endpoints

 

2) Rett's trial data to be released 

 

3) Possible Partnership Announcement

 

         I am hoping at least one of these gets our share price over $15.00. Two or more and I'm hoping we don't look back. AIMHO

 

                                                   Best Regards,

 

                                                             Gare